Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/EBITDA ratio high or low?
The EV/EBITDA ratio of 0.21x is 600% above its estimated 1-year average of 0.03x, near the high end of its estimated 1-year range (0.02x–0.21x).
As of 2026-10-06T13:25:57.814Z.
Calculation as of: 2026-10-06T13:25:57.814Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
0.21x
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
15.24x
median of 158 covered companies
CURRENT VS SECTOR MEDIAN
-98.62%
vs the sector median at left
Market Cap
$67.11M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $63.98M | 0.21x | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $64.56M | N/A | 7.83x | 18.88x | 17.80x |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $66.56M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $67.11M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.78M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.48M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.29M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.05M | 260.01x | 103.53x | 75.29x | 64.49x |
At 0.2, EV/EBITDA is above its estimated 1-year median — higher than 100% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
0.0
median
0.0
estimated 1-year high
0.1
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-10-05 | 0.02x |
| 2026-10-02 | 0.02x |
| 2026-10-01 | 0.02x |
| 2026-09-30 | 0.02x |
| 2026-09-29 | 0.02x |
| 2026-09-28 | 0.02x |
| 2026-09-25 | 0.02x |
| 2026-09-24 | 0.03x |
| 2026-09-23 | 0.03x |
| 2026-09-22 | 0.03x |
| 2026-09-21 | 0.03x |
| 2026-09-18 | 0.03x |
| 2026-09-17 | 0.03x |
| 2026-09-16 | 0.03x |
| 2026-09-15 | 0.03x |
| 2026-09-14 | 0.03x |
| 2026-09-11 | 0.03x |
| 2026-09-10 | 0.03x |
| 2026-09-09 | 0.03x |
| 2026-09-08 | 0.03x |
| 2026-09-04 | 0.03x |
| 2026-09-03 | 0.03x |
| 2026-09-02 | 0.03x |
| 2026-09-01 | 0.03x |
| 2026-08-31 | 0.03x |
| 2026-08-28 | 0.04x |
| 2026-08-27 | 0.04x |
| 2026-08-26 | 0.04x |
| 2026-08-25 | 0.05x |
| 2026-08-24 | 0.04x |
| 2026-08-21 | 0.04x |
| 2026-08-20 | 0.04x |
| 2026-08-19 | 0.03x |
| 2026-08-18 | 0.03x |
| 2026-08-17 | 0.03x |
| 2026-08-14 | 0.03x |
